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Abstract: Alzheimer’s disease (AD) is the most common neurodegenerative disorder. Worldwide prevalence of the dis-
ease is estimated at more than 24 million cases. With aging of populations, this number will likely increase to more than 
80 million cases by the year 2040. The annual incidence worldwide is estimated at 4.6 million cases which is the equiva-
lent of one new  case every  seven seconds! The pathophysiology of AD is complex and largely misunderstood. It  is 
thought to start with the accumulation of beta-amyloid (Aβ) that leads to deposition of insoluble neuritic or senile plaques. 
Secondary events in this “amyloid cascade” include hyperphosphorylation of the protein tau into neurofibrillary tangles, 
inflammation, oxidation, and excitotoxicity that eventually cause activation of apoptotis, cell death and neurotransmitter 
deficits. This review will briefly summarize recent advances in the pathophysiology of AD and focus on the pharmacol-
ogical treatment of the cognitive and functional symptoms of AD. It will discuss the roles of vascular prevention, cholin-
esterase inhibitors and an NMDA-antagonist in the management of AD. It will address the issues thought to be related to 
the lack of persistence or discontinuation of therapy with cholinesterase inhibitors shown in recent studies and some of the 
solutions proposed. These include setting realistic expectations in light of a neurodegenerative condition and available 
symptomatic treatments, slowly titrating medications, and using alternate routes of administration. Finally, it will intro-
duce future therapeutic options currently under study.  
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INTRODUCTION 
  The year 2006 marked the centennial of the description 
by Alois Alzheimer of the first case of the disease that will 
eventually hold his name. Alzheimer’s disease (AD) is the 
most  common  neurodegenerative  disorder.  Worldwide 
prevalence of dementia is estimated at more than 24 million 
cases [44]. The annual incidence worldwide is estimated at 
4.6 million cases which is the equivalent of one new case 
every seven seconds ! [44]. With aging of populations, this 
number will double every twenty years, likely increasing to 
more than 80 million cases by the year 2040 [44]. Aging is 
amongst the major risk factors for the disease. For example, 
in the Canadian Study on Health and Aging, close to 10% of 
all individuals aged 65 and older were affected by dementia 
and this rose to 35% in individuals aged 85 and older [21].  
Most  cases  of  dementia  are  due  to  AD  with  or  without  
a  cerebrovascular  contribution  [23].  The  global  burden  of 
disability associated with dementia in the elderly is believed 
to be higher  than  in stroke, musculoskeletal disease, heart 
disease and cancer. Finally, the annual cost of dementia in 
the UK (17 billion pounds) is estimated to be higher than the 
costs of heart disease, stroke and cancer combined [19]. This  
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review  will  briefly  summarize  recent  advances  in  under-
standing the pathophysiology of AD and focus on the phar-
macological treatment of cognitive and functional symptoms 
of the disease. It will discuss the roles of vascular preven-
tion, cholinesterase inhibitors, and an NMDA-antagonist in 
the management of AD. It will address the issues thought to 
be  related  to  the  lack  of  persistence  or  discontinuation  of 
therapy with cholinesterase inhibitors shown in recent stud-
ies and some of the solutions proposed. These include setting 
realistic expectations, slow titration of the medications, and 
alternate  routes  of  administration.  It  will  introduce  future 
therapeutic options currently under study. 
PATHOPHYSIOLOGY 
  The pathophysiology of AD is complex and incompletely 
understood. Several hypotheses have been suggested to ex-
plain the series of events that eventually lead to the clinical 
manifestations of the disease. Presently, the two main com-
peting  hypotheses  are  the  amyloid-cascade  hypothesis  and 
the  hyperphosphorylation  of  protein  tau  hypothesis,  which 
are  ardently  supported  by  the  so-called  “baptists”  and 
“tauists” respectively [92]. These hypotheses are represented 
histologically by the two hallmarks that are still used today 
to  reach  a  definite  diagnosis  of  AD:  amyloid  plaques  and 
neurofibrillary  tangles  (NFT)  [16,  17].  In  AD,  amyloid 
plaques are found in the entorhinal cortex, the hippocampus 
and neocortical areas [37, 111, 131]. These plaques are also 
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correlate with progression of dementia. Neurofibrillary tan-
gles are deposited in a hierarchical and systematic fashion 
that correlates closely with cognitive decline in AD [7, 18, 
67].  They  start  in  the  entorhinal  cortex  and  sequentially 
spread to the hippocampus, the rest of the temporal lobe, the 
association areas of the prefrontal and parietal cortices, and 
eventually  reach  all  neocortical  areas  [35].  Neurofibrillary 
tangles are also observed in other neurodegenerative disor-
ders.  Several  arguments  support  the  amyloid-cascade  hy-
pothesis as the predominant one. In humans, amyloid precur-
sor protein (APP) found on chromosome 21undergoes cleav-
age by three enzymatic complexes: α-secretase, β-secretase, 
and γ-secretase [111, 112] (Fig. 1). Sequential cleavage of 
APP by α-secretase and γ-secretase leads to the production 
of a small, non-toxic, and soluble peptide, referred to as p3. 
The  sequential  cleavage  of  APP  by  β-secretase  and  γ-
secretase  leads  to  the  production  of  the  insoluble  beta-
amyloid  protein  that  deposits  into  plaques.  Beta-amyloid 
(Aβ) is neurotoxic in vitro [27, 81, 89]. The mouse model of 
AD  over-expressing  the  Amyloid  Precursor  Protein  (APP) 
gene shows amyloid plaques similar to the ones found in the 
brains of AD patients. These  mice also display  short-term 
memory and learning deficits on specifically designed tests 
[66].  In  humans,  all  individuals  with  clinical  AD  have  
abnormal deposits of Aβ (diffuse or neuritic plaques) [59]. 
Individuals with Down’s syndrome, who have three copies 
of  chromosome  21,  almost  invariably  express  clinical  and 
pathological features of AD by mid-life [62]. All mutations 
described in the rare autosomal-dominant forms of AD affect 
APP and γ-secretase and are associated with increased depo-
sition of Aβ [3, 75, 83, 107]. Apolipoprotein E4, the main  
genetic risk factor for sporadic AD, is associated with in-
creased production and deposition of Aβ [25, 108]. Genera-
tion of specific antibodies against Aβ in individuals with AD 
has been associated with mild and inconsistent clinical im-
provement and clearing of amyloid plaques in some patients 
[55,  62].  According  to  the  amyloid-cascade  hypothesis,  
abnormal generation (or insufficient clearance of Aβ) leads 
to several secondary events including hyperphosphorylation 
of the protein tau and generation of neurofibrillary tangles, 
inflammation,  oxidation,  and  excitotoxicity  [60,  84,  86]. 
These events lead in turn to the activation of the apoptotic 
cascade, neuronal cell death and neurotransmitter deficits. It 
is the deficit in acetylcholine, and to a lesser extent in nore-
pinephrin and serotonin, that is thought to be responsible for 
the clinical manifestations of the disease [51].  
  The  main  alternate  hypothesis  to  the  amyloid  cascade 
lends a central role to hyperphosphorylation of the protein 
tau. This protein normally binds and stabilizes microtubules, 
the main component of the cellular cytoskeleton. In AD, tau 
is  hyperphosphorylated  leading  to  the  formation  of  paired 
helical filaments (PHF) and eventually NFTs [56, 74, 125]. 
These  structures  disrupt  neuronal  transport  and  eventually 
lead to cell death. The specific timing and chronology of the 
interaction between deposition of Aβ and hyperphosphoryla-
tion of tau is still controversial. Animal studies show that the 
presence of abnormal  tau potentiates Aβ toxicity [2, 102]. 
This is supported by clinicopathological data suggesting that 
NFTs mediate the  effect of amyloid deposition on clinical 
disease [5].  
  Recent data suggest that cerebrovascular disease plays an 
important role in the pathophysiology of AD. There are epi-
demiological, clinical and pathological similarities between 
AD and vascular dementia. Also, regional brain hypoperfu-
sion leading to hypometabolism, degenerative changes and 
cognitive impairment have been described in early stages of 
AD. These principles are known as the Critically Attained 
Threshold of Cerebral Hypoperfusion (CATCH) theory [30]. 
According to this controversial hypothesis, regional hypoper-
fusion is the primary trigger of the degenerative cascade de-
scribed  earlier  [1,  31,  32,  33].  Clinicopathological  studies 
published recently show that most cases of dementia are due 
to a contribution of degenerative and cerebrovascular lesions 
(so-called “mixed dementia”) [91, 109]. In fact, some studies 
suggest that as individuals age, the contribution of amyloid 
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plaques and NFTs to clinical dementia decreases [42, 106], 
and that concomitant cerebrovascular lesions play a crucial 
role  in  modulation  of  the  clinical  expression  of  cognitive 
impairment [118, 126].  
PHARMACOLOGICAL TREATMENT 
Clinical Outcomes in Clinical Trials 
  Alzheimer’s  disease  progressively  impairs  cognitive 
abilities and behaviour, leading to gradual functional decline. 
Outcome measures used in clinical trials are selected to mir-
ror clinical hallmarks of the disease. Typically, these trials 
include  a  combination  of  measures  evaluating  cognition, 
clinicians’ and caregivers’ impression of change, functional 
abilities and behaviour. Pharmacological treatment of behav-
ioural  and  psychological  symptoms  of  dementia  (BPSD) 
have  been  recently  reviewed  in  this  journal  [77].  We  will 
focus on cognitive, global, and functional outcomes. Cogni-
tive outcome measures include the Alzheimer’s Disease As-
sessment  Scale  –  cognitive  subscale ( ADAS-Cog  -  scored 
from 0-70, a higher number indicating worse performance) 
[105], the Mini-Mental Status Examination (MMSE – scored 
from 0-30, a higher number indicating better performance) 
[49], and the Severe Impairment Battery (SIB – scored 0-100, 
a higher number indicating better performance) [97]. Global 
measures include the Clinical Global Impression of Change 
(CGIC – scored from 1 to 7, 4 indicating no change, 1 and 7 
indicating significant improvement and significant deteriora-
tion  respectively)[110],  and  the  Clinician  Interview-Based 
Impression of Change (CIBIC – scored from 1 to 7 similarly 
to  the  CGIC)  [72].  Functional  measures  include  the  
Progressive Deterioration Scale (PDS – scored from 0-100, 
a  higher  number  indicating  better  performance)  [34],  the 
Alzheimer’s  Disease  Cooperative  Study  Activities  of  Daily 
Living inventory (ADCS-ADL – scored 0-78, a higher score 
indicating  worse  performance)  [52],  and  the  Disability  
Assessment  for  Dementia  scale ( DAD  –  scored  0-100%,  a 
higher number indicating better performance) [54].  
Vascular Prevention 
  Results of clinical trials in primary prevention of AD are 
contradictory. Three studies have shown that optimal use of 
antihypertensive agents in systolic and diastolic hypertension 
as well as after a cerebrovascular event is associated with a 
reduction in the incidence of cognitive impairment [50, 123, 
127]. The recently completed Hypertension in the Very Eld-
erly Study (HYVET) however showed that treatment of in-
dividuals 80 years of age or older is associated with a reduc-
tion in cardiovascular and cerebrovascuar end-points, but not 
in cognitive impairment [4, 98]. In two major primary pre-
vention trials,  cholesterol-lowering agents in  individuals at 
risk lead to a reduction in cardiovascular and cerebrovascular 
events but had no benefit on cognitive outcomes [24, 114]. A 
secondary prevention trial in individuals with mild cognitive 
deficits (loosely defined as a MMSE between 20-28) com-
paring two treatments of systolo-diastolic hypertension did 
not show any difference between the drugs in terms of cogni-
tive  outcomes.  Individuals  with  the  best  improvements  in 
blood  pressure  measures  benefited  the  most  on  working 
memory measures [119]. A prospective observational study 
shows that treatment of vascular risk factors in individuals 
with AD is associated with a slower cognitive decline [36]. 
There are no published intervention trials in tertiary vascular 
prevention in AD. These results have led the Canadian Con-
sensus Conference on Diagnosis and Treatment of Dementia 
(CCCDTD) to recommend treatment of high blood pressure 
as an option in the prevention of cognitive decline (Grade B, 
Level I recommendation) [12]. 
Cholinesterase Inhibitors 
  Neurochemical  studies  of  neurons  from  the  basal  fore-
brain of individuals with AD have shown a deficit in choline 
acetyl-transferase leading to a decrease in the production of 
acetylcholine  and  cortical  cholinergic  dysfunction  [128]. 
These  studies  suggested  that  acetylcholine  replacing  or  
enhancing therapies might be of benefit in individuals with 
AD.  Acetylcholine  precursors  and  cholinergic  receptor  
agonists were used in clinical trials, but abandoned for lack 
of  effectiveness  or  intolerable  side  effects  [13,  41,  124]. 
Cholinesterase  inhibitors  (ChEI)  act  by  inhibiting  the  en-
zymes  (acetyl-  and  butyryl-cholinesterase)  responsible  for 
the breakdown of acetylcholine hence increasing  its  avail-
ability at the synaptic cleft. In a within-subject pilot study 
including  13  individuals  with  Alzheimer’s  disease  and  18 
healthy controls, physostigmine improved memory by opti-
mizing extrastriate selectivity as detected by functional mag-
netic resonance imaging [6]. Three ChEI’s are widely avail-
able and will be discussed in this paper: donepezil, rivastig-
mine,  and  galantamine.  They  are  considered  symptomatic 
treatments as they improve symptoms without modifying the 
course of the disease. 
Donepezil 
  Donepezil is a piperidine derivative that reversibly inhib-
its acetylcholinesterase [113]. It is very well absorbed after 
oral administration and reaches peak plasmatic concentration 
(Cmax)  in  3-4  hours.  Elimination  half-life  of  donepezil  is 
approximately 70 hours allowing once daily administration. 
It binds to plasma proteins in a proportion of 96%, and is 
metabolised  by  isoenzyme  2D6  and  3A4  of  cytochrome 
P450.  Starting  and  minimal  effective  dose  is  5  mg  once 
daily. Maximal recommended dose is 10 mg daily.  
  A recently published Cochrane review evaluating done-
pezil in AD included 24 trials and 5796 participants in mild 
to  severe  stages  of  the  disease  [9].  It  showed  statistically 
significant improvement versus placebo at 24 weeks (ADAS-
Cog and SIB) and 52 weeks (MMSE). There was statistically 
significant improvement versus placebo on the CIBIC-plus at 
24 weeks. There were also statistically significant benefits on 
the DAD at 24 weeks, the ADCS-ADL (version for moderate 
to severe AD) at 24 weeks, and PDS at 52 weeks. Overall, 
both the doses of 5 mg and 10 mg were beneficial, with the 
higher  dose  being  marginally  more  effective.  More  side-
effects were reported with donepezil than with placebo. Most 
common side-effects were nausea, vomiting, diarrhoea, mus-
cle cramps, dizziness, fatigue, and anorexia, and they were 
dose-dependent.  The  authors  conclude: “People with  mild, 
moderate or severe dementia due to AD treated for periods 
of 12, 24, 52 weeks with donepezil experienced benefits in 
cognitive  function,  activities  of  daily  living…Study  clini-
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patients,  and  measured  less  decline  in  measures  of  global 
disease  severity.”  A  positron  emission  tomography  (PET) 
evaluated  acetylcholinesterase  (AChE)  activity  in  14  indi-
viduals with AD before and after treatment with donepezil 
[14].  The  results  show  a  modest  inhibition  of  AChE  with 
treatment that is most apparent in the cingulated cortex, and 
correlates with performance on tests of  executive function 
and attention. A single photon emission computerized tomo-
graphy (SPECT) study in 51 patients with AD before and 
after a 10-14 month treatment period with donepezil showed 
differential  perfusion  patterns  in  stabilized  and  non-
stabilized individuals (based on their MMSE scores) [115]. 
In  non-stabilized  patients,  there  was  lower  cerebral  blood 
flow on SPECT in the lateral and medial frontal lobes, limbic 
lobe, lower lateral temporal lobe, and cingulated gyrus com-
pared  to  the  stabilized  patients.  The  authors  conclude  that 
SPECT may be useful in evaluating the brain function re-
sponse to ChEI therapy.  
Rivastigmine 
  Rivastigmine  is  a  carbamate  derivative  that  reversibly 
inhibits both acetyl- (AChE) and butyryl- (BuChE) cholines-
terase [95]. It is the only ChEI with significant inhibition of 
BuChE.  Butyrylcholinesterase  is  widely  distributed  in  the 
central nervous system and may play a role in cholinergic 
function  and  neurodegeneration  [29].  It  is  unclear  how  
specific BuChE  inhibition relates to rivastigmine’s  clinical 
effect. Rivastigmine is well absorbed after oral administra-
tion and reaches Cmax in one hour. Its elimination half-life 
is  approximately  1  to  2  hours.  It  binds  to  proteins  in  a  
proportion  of  40%,  is  hydrolysed  by  esterases  (including 
cholinesterases),  and  is  excreted  in  the  urine.  Cytochrome 
P450 isoenzymes are not involved in the metabolism of ri-
vastigmine hence minimizing drug-drug interactions. Start-
ing dose of rivastigmine is 1.5 mg twice a day and can be 
gradually titrated to the maximal dose of 6 mg twice a day. 
The minimal effective dose is 3mg twice a day. A transder-
mal form of rivastigmine has been developed and is available 
on most markets since 2008 [10, 130]. The main objective of 
transdermal rivastigmine is to allow titration to the highest 
(and most therapeutic) doses of the medication while mini-
mizing side effects. This is achieved by slow release of the 
medication into the circulation as demonstrated by a Cmax 
of 8 hours by transdermal route. Starting dose of transdermal 
rivastigmine is 5 cm
2, and the effective and maximal dose is 
10 cm
2. 
  A  Cochrane  review  evaluating  rivastigmine  in  AD  has 
recently been updated and includes 9 trials and 4775 patients 
[8].  It  shows  that  rivastigmine  at  high  doses  (6  to  12  mg 
daily) is associated with statistically significant improvement 
versus  placebo  at  26  weeks  on  cognitive  (ADAS-Cog), 
global  (CIBIC-plus)  and  functional  outcomes  (PDS).  The 
results are more subtle on lower doses (4 mg daily or lower), 
reaching statistical significance for cognitive outcomes only. 
More side-effects were reported with rivastigmine than with 
placebo and they were dose-dependent. Most common side-
effects  were  nausea,  vomiting,  diarrhoea,  anorexia,  head-
ache, syncope, abdominal pain and dizziness. The recently 
published  Investigation  of  transDermal  Exelon  in  Alz-
heimer’s  disase  (IDEAL)  study  compared  two  doses  of 
transdermal  rivastigmine  with  the  oral  form  [130].  The 
Table 1.  Pharmacologic Properties of Widely Approved Alzheimer’s Disease Treatments 
Name  Mechanism of  
Action 
Elimination 
Half-life 
Protein 
Binding 
Metabolism  Starting  
Dose 
Effective  
Dose 
Maximal  
Dose 
Donepezil  .Acetylcholinesterase  
inhibitor 
.Piperidine derivative 
70 hours  96%  .Hepatic 
.Cytochrome P450  
– 2D6 and 3A4 
5mg once daily  5mg once daily   10 mg once daily 
Rivastigmine 
(Oral) 
.Acetylcholinesterase  
inhibitor 
.Butyrylcholinesterase  
inhibitor 
.Carbamate derivative 
1-2 hours  40%  Urinary  1.5 mg twice 
daily 
3.0 mg twice 
daily 
6 mg twice daily 
Rivastigmine 
(Transdermal) 
.Acetylcholinesterase  
inhibitor 
.Butyrylcholinesterase  
inhibitor 
.Carbamate derivative 
1-2 hours  40%  Urinary  5 cm
2  10 cm
2  10 cm
2 
Galantamine ER  .Acetylcholinesterase  
inhibitor 
.Nicotinic allosteric agonist  
.Tertiary alkaloid 
7-8 hours  18%  .Hepatic 
.Cytochrome P450  
– 2D6 and 3A4 
8 mg once daily  16 mg once daily  24 mg once daily 
Memantine  .N-Methyl-D-Aspartate 
(NMDA)  
non-competitive  
receptor antagonist 
60-80 hours  45%  Urinary  5 mg daily  
(in 1 or 2 doses) 
10 mg daily  
(in 1 or 2 doses) 
20 mg daily  
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higher  20  cm
2  dose  (not  commercially  available)  was  not 
associated with more clinical benefit and led to more side-
effects. The smaller 10 cm
2 dose which is the highest com-
mercially available dose was associated with similar clinical 
benefit  than  the  maximal  oral  dose,  but  with  significantly 
less gastrointestinal side-effects. Neither dose of transdermal 
rivastigmine  led  to  behavioural  benefits  compared  to  pla-
cebo. The authors of the Cochrane review conclude: “ Rivas-
tigmine  appears  to  be  beneficial  for  people  with  mild  to 
moderate Alzheimer’s disease…improvements were seen in 
the rate of decline of cognitive function, activities of daily 
living, and severity of dementia…”. A plasma and Cerebro-
spinal fluid (CSF) biomarker study evaluated the long-term 
ChEI inhibitory effect of rivastigmine in eleven patients with 
AD treated for 12 months. This uncontrolled study showed 
persistent inhibition of both AChE and BuChE in plasma as 
well  as  CSF  [28].  This  contrasts  with  studies  with  other 
ChEI’s which are usually  associated with up-regulation of 
cholinesterases. This up-regulation is sometimes invoked to 
explain the relatively short duration of effect of these medi-
cations.  However,  the  relative  “lack”  of  up-regulation  of 
ChE with rivastigmine has not been unequivocally shown to 
relate to more sustained clinical benefit.  
Galantamine 
  Galantamine  is  a  tertiary  alkaloid  agent  that  reversibly 
inhibits AChE [103]. It also binds allosterically to nicotinic 
receptors enhancing cholinergic function. The clinical rele-
vance of allosteric binding to nicotinic receptors in humans 
is  unclear.  Galantamine  is  rapidly  absorbed  after  oral  ad-
ministration  and  reaches  Cmax  in  approximately  1  hour. 
Elimination  half-life  is  between  7  to  8  hours.  It  binds  to 
plasma proteins in a proportion of 18% and is metabolized 
by  isoenzyme  2D6  and  3A4  of  cytochrome  P450.  Galan-
tamine is commercialized as an extended-release formulation 
allowing once-daily dosing. Starting dose of galantamine ER 
is 8 mg once daily. Minimal effective dose is 16 mg daily, 
and maximal dose is 24 mg daily.  
  A recently published Cochrane review evaluating galan-
tamine in mild to moderate AD and Mild Cognitive Impair-
ment (prodrome of dementia) included 10 trials and a total of 
6805 participants [80]. It showed statistically significant im-
provement versus placebo at 24 weeks on the ADAS-Cog, 
and the CIBIC-plus. Functional measures (ADCS-ADL and 
DAD) were seldom included in these clinical trials, but they 
showed statistical significance in individual trials. In contrast 
to  other  clinical  trials  with  ChEI,  there  was  no  consistent 
dose-response  effect  in  doses  above  8mg  daily.  Galan-
tamine’s  side  effects  are  comparable  to  other  ChEI’s  and 
consist mainly of cholinergic gastrointestinal symptoms. The 
authors conclude: “…this review shows consistent positive 
effects  for  galantamine  for  trials  of  three  to  six  months’  
duration.  Although  there  was  not  a  statistically  significant 
dose-response effect, doses above 8mg/d were, for the most  
part, consistently statistically significant.” A randomized trial  
of  galantamine  in  individuals  with  vascular  dementia  and 
AD  with  a  cerebrovascular  contribution  (so-called  “mixed  
dementia”)  showed  statistically  significant  benefits  versus 
placebo on the ADAS-Cog, the CIBIC-plus, and the DAD 
[40]. The results of this trial has led a group of experts to 
recommend  galantamine  as  “a  treatment  option  for  mixed 
AD with cerebrovascular disease” (Grade B, Level I recom-
mendation) [12]. A PET study evaluated the effects of galan-
tamine treatment on AChE and nicotinic receptor binding in 
18 patients with mild AD over 12 months [68]. It shows sus-
tained  cortical  inhibition  of  AChE.  Overall,  there  was  no 
statistically significant change in nicotine binding. However, 
both cholinesterase inhibition and nicotine binding correlated 
positively with performance on a test of attention in these 
patients.  A  recently  published  study  used  functional  mag-
netic resonance imaging in two tasks of visual perception in 
8 individuals with AD before and after a three-month trial of 
galantamine [15]. It showed a decrease in the activation of 
the  dorsal  visual  pathway  with  treatment  suggestive  of  a 
more efficient processing of visual stimuli or a modification 
in the compensatory changes observed in AD.  
Comparative Studies of Cholinesterase Inhibitors 
  Four clinical trials compared the ChEI’s in AD and led to 
conflicting results [58]. A careful review of the methodology 
of three of these trials using the Consolidated Standards of 
Reporting Trial (CONSORT) checklist concluded that 27% 
to 55% of these criteria per study were inadequately reported 
[64]. Considering these serious methodological limitations in 
comparison  studies,  one  cannot  favour  one  ChEI  over  the 
other at this point. Nevertheless, differences in  tolerability 
were noted in one meta-analysis and led authors to conclude 
that “ across studies, the frequency in which these (adverse) 
events were reported was generally lowest for donepezil and 
highest for rivastigmine” [58]. On this issue, the CCCDTD 
concludes: “Although all three ChEI’s available in Canada 
have efficacy for mild to moderate AD, equivalency has not 
been  established  in  direct  comparison.  Selection  of  which 
agent to be used will be based on adverse effect profile, ease 
of use, familiarity, and beliefs about the importance of the 
differences between the agents in their pharmacokinetics and 
other mechanisms of action.” [63].  
Memantine 
  Studies have shown that enhancement of the excitatory 
effects  of  the  neurotransmitter  glutamate  may  play  a  role  
in the pathogenesis of AD (theory of “excitotoxicity”) [120]. 
Memantine  is  a  N-methyl-D-aspartate  (NMDA)  non-com- 
petitive  glutatmate  receptor  antagonist  [70].  It  is  well  
absorbed  after  oral  administration  and  reaches  Cmax  in  3  
to 8 hours. Elimination half-life is 60-80 hours. It binds to 
proteins in a proportion of 45%, and is almost completely 
excreted unchanged in the urine. Starting dose is 5 mg daily 
(in one or two doses). Minimal therapeutic dose is 10 mg 
daily, and maximal dose is 20 mg daily. 
  The Cochrane review evaluating memantine included 3 
clinical  trials  in  moderate  to  severe  AD  and  three  unpub-
lished studies in mild to moderate AD [90]. In moderate to 
severe AD, pooled data show statistically significant benefits 
versus placebo at 6 months on measures of cognition (SIB), 
function  (ADCS-ADL  severe  version),  and  global  impres-
sion (CIBIC-plus). In mild to moderate AD, analyses show 
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(ADAS-cog) that do not translate into significant differences 
on measures of global impression and function. Memantine 
is generally well tolerated. Some studies suggest a reduced 
frequency  of  agitation  and  agressivity  versus  placebo,  
although the meta-analysis suggests an overall increased risk 
of  agitation  compared  to  placebo.  The  authors  conclude: 
“Memantine has  a small beneficial effect at six months in 
moderate to severe AD.” In most countries where it is avail-
able,  memantine  is  approved  for  treatment  of  moderate  to 
severe AD. A clinical trial compared the added efficacy of 
memantine in patients with moderate to severe AD receiving 
stable doses of donepezil [122]. It shows additional benefits 
of  memantine  versus  placebo  on  the  SIB,  ADCS-ADL,  
and CIBIC-plus. Theses results suggest that memantine has 
an additive effect on ChEI’s in moderate to severe AD. A 
randomized placebo-controlled study is under way in Canada 
to determine if memantine reduces the incidence and severity 
of agitation and agressivity. 
Cost-Effectiveness of Symptomatic Treatments 
  Relatively  few  clinical  trials  have  evaluated  cost-
effectiveness  of  pharmacological  treatment  in  AD.  The 
Cochrane review on donepezil considered the results of the 
two  trials  allowing  cost-benefit  evaluation  and  concluded: 
“There  is  some  evidence  that  use  of  donepezil  is  neither 
more nor less expensive compared with placebo when  as-
sessing total health care resource cost.”[9, 46]. Several cost-
effectiveness modeling studies have shown results in favour 
of ChEI [45]. These analyses are based mainly on the cogni-
tive, functional and behavioural benefits provided by these 
medications that eventually allow delaying long-term institu-
tionalisation. A significant portion of excess cost associated 
with AD is due to hospitalisations and post-acute care and 
this is difficult to include in cost-effectiveness models. The 
AD  2000  study  aimed  at  evaluation  pharmacoeconomic 
benefits of ChEI’s in AD. The main objectives of this non-
industry sponsored clinical trial were to assess the effects of 
donepezil  treatment  on  delaying  institutionalisation  and 
functional  deterioration  in  mild  to  moderate  AD  [26].  It 
showed  statistically  significant  benefits  on  cognitive  and 
functional measures that did not lead to a delay in institu-
tionalisation and functional deterioration. The authors of this 
study concluded: “donepezil is not cost-effective, with bene-
fits  below  minimally  relevant  thresholds.”  Unfortunately, 
this study suffers from several serious methodological limita-
tions including a small number of individuals at the start of 
the  trial  compromising  the  power  of  analyses,  repeated 
washout periods during follow-up, and significant attrition of 
patients with follow-up. Secondary analyses of other clinical 
trials and observational data have also shown results favour-
ing  pharmacological  treatment.  For  example,  secondary 
analyses  of  clinical  trials  with  donepezil  and  galantamine 
show that the magnitude of “exposure” to the drug in terms 
of doses and duration is associated with a delay in institu-
tionalisation [43, 53]. Two observational studies of patients 
evaluated  and  treated  in  AD  research  centers  show  that 
treatment  with  ChEI’s  delays  institutionalisation  [78,79]. 
Memantine  provides  an  additional  benefit  to  ChEI  in  one 
study  [78].  These  results  are  encouraging  but  need  to  be 
validated  in  well-designed  randomised  clinical  trials  
prospectively considering all aspects of resource utilization 
and indirect costs leading to a reliable and satisfying cost-
effectiveness analysis.  
Summary Of Clinical Benefit From Symptomatic Treat-
ments and Recommendations 
  Overall,  the  benefits  of  symptomatic  treatments  in  AD 
are modest. Some authors argue that the magnitude of this 
benefit,  though  statistically  significant,  is  marginal  at  best 
and may even be difficult to detect, measure  and quantify 
clinically [69, 100]. A metanalysis of 20 studies with ChEI’s 
specifically  evaluated  measurability  and  quantification  of 
clinical benefit [104]. This study considered two measures of 
Effect Size (ES) as indicators of the magnitude of response 
leading  it  to  be  clinically  detectable.  Effect  Size  is  deter-
mined  by  calculating  the  absolute  difference  in  effect  be-
tween the treatment and placebo groups, in relation to the 
variance of the given measure. Effect size is usually consid-
ered mild if between 0.2 and 0.4 and moderate when it falls 
between 0.41 and 0.7. The analyses show that median ES for 
ADAS-Cog varies from 0.15 to 0.47 depending on doses of 
ChEI. The same values were obtained for ES on the CIBIC-
plus. The author concludes that ChEI’s produce benefits that 
are mild to moderate, which are dose-dependent, and more 
importantly,  reproducible  across  clinical  trials.  Another 
metanalysis  of  16  studies  evaluated  Numbers  Needed  to 
Treat  (NNT)  for  clinical  benefits  and  Numbers  Needed  to 
Harm  (NNH)  for  side-effects  of  ChEI’s  [73].  This  study 
shows that 12 patients would need to be treated to observe 
minimal improvement or better on measures of cognition and 
global evaluation. The NNT for stabilisation or improvement 
is 7. NNH for one additional patient to experience an adverse 
event is 12.These figures compare very favourably to other 
well accepted interventions in medicine [47]. How do these 
results translate into clinical practice? In mild to moderate 
AD, clinical trials usually produce maximal improvement on 
cognitive measures after three months of treatment, but allow 
stabilisation of cognition for a period varying between 9 and 
12 months. On measures of global impression, maximal im-
provement is observed at 3 months, and stabilisation usually 
lasts for about 6 months. On measures of function, the re-
sponse  usually  observed  is  stabilisation  rather  than  im-
provement. Functional capacities lost (for example managing 
finances  or  driving)  are  seldom  recuperated  with  sympto-
matic treatment.  
  Published guidelines on symptomatic treatment for AD 
vary in the strength of their recommendations. Certain con-
sensus  guidelines  consider  at  least  a  trial  of  ChEI  and/or 
memantine  as  a  standard  approach  in  the  pharmacological 
treatment of AD. These include the recommendations from 
the American Academy of Neurology [39] , the British Asso-
ciation of Psychopharmacology [20], the American Associa-
tion  for  Geriatric  Psychiatry  [82],  Recommendations  for 
Best  Practices  in  the  Treatment  of  AD  in  Managed  Care 
[47], and the Canadian Consensus Conference of Diagnosis 
and  Treatment  dementia  [63].  For  example,  the  CCCDTD 
states  that  “all  three  cholinesterase  inhibitors  available  in 
Canada are modestly efficacious for mild to moderate AD. 
They are  all viable options for most patients with mild to 
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AAN recommends that: “cholinesterase inhibitors should be 
considered in patients with mild to moderate AD (Standard), 
although studies suggest a small average degree of benefit.” 
The  consensus  statement  from  the  British  Association  for 
Psychopharmacology states: “There is type 1a evidence for 
the efficacy of memantine in the treatment of moderate to 
severe Alzheimer’s disease”. Conversely, the National Insti-
tute for Health and Clinical Excellence (NICE) in the UK 
made  the  following  recommendations  based  on  a  cost-
effectiveness evaluation of ChEI’s in AD: “The three aceth-
ylcholinesterase inhibitors donepezil, galantamine, and rivas-
tigmine are recommended as options in the management of 
patients  with  Alzheimer’s  disease  of  moderate  severity 
only.” [93]. They add: “Memantine is not recommended as a 
treatment option for patients with moderately severe to se-
vere  Alzheimer’s  disease  except  as  part  of  well  designed 
clinical  studies”.  The  clinical  practice  guidelines  from  the 
American College of Physicians and the American Academy 
of Family Physicians conclude : “Clinicians should base the 
decision  to initiate  a  trial of  therapy with  a  cholinesterase 
inhibitor or memantine on individualized assessment.” [99, 
100].  This  assessment  should  take  into  consideration  the 
“clinically marginal” benefits, the heterogeneous and unpre-
dictable response in an individual patient, the potential for 
side-effects, and stage of the disease.  
Drug Utilisation Studies of Pharmacological Treatments 
in AD 
  Two observational administrative database studies evalu-
ated persistence with the three available ChEI in two Cana-
dian  provinces  [61,  85].  The  study  from  Quebec  included 
18748 individuals and the study from Ontario 5622 individu-
als, all aged 65 and older. Persistence rates at one year varied 
between 40% and 54% among individual ChEI’s in the On-
tario study. In the Quebec study, the overall persistence rate 
for the drug class was 40% at one year. Both studies showed 
better persistence with galantamine as compared to donepezil 
and rivastigmine. The reason for this finding is unclear, but 
the reproducibility of this result across two different prov-
inces is intriguing. Two studies from the US evaluated per-
sistence with donepezil and rivastigmine [117, 121]. While 
mean  duration  of  use  were  well  below  one  year  for  both 
drugs,  there  was  no  difference  in  persistence  between  the 
two. Among the hypothesis evoked to explain these disap-
pointingly low rates of persistence with ChEI’s are: toler-
ance, lack of familiarity with the drugs by primary care phy-
sicians, and unrealistic expectations by physicians, patients 
and their caregivers. Tolerance to these medications can be 
optimized by starting at low doses and slowly and individu-
ally titrating in no less than four-week interval periods. Al-
ternate routes of administration such as the transdermal for-
mulation of rivastigmine can significantly enhance tolerance 
by  minimizing  usual  cholinergic  side-effects.  Alzheimer’s 
disease is a progressive neurodegenerative disease and avail-
able  treatments  do  not  modify  progression  of  the  process. 
Expectations  with  ChEI  treatment  need  to  be  adapted  to 
these  realities.  In  that  sense,  even  stabilisation  of  clinical 
symptoms for 6  to 12 months  is  considered an  acceptable 
response  to  treatment.  Slower  deterioration  for  individual 
patients is more challenging to establish in clinical practice 
than  in  clinical  trials  where  data  from  placebo  groups  are 
readily  available  for  comparison.  Clinically,  an  individual 
patient’s deterioration can be compared to published data on 
the natural history of progression of untreated AD [47]. Pub-
lished recommendations are vague as to the determinants of 
the  duration  of  pharmacological  treatment  in  AD  and  the 
specific criteria for discontinuation.  
FUTURE TREATMENTS 
Dimebon (Latrepirdine) 
  Latrepirdine is a non-selective anti-histaminic agent that 
has  been  used  as  an  anti-allergic  medication  in  Eastern 
Europe. In vitro and in animal models of AD, it has been 
shown to have mitochondrial stabilizing properties leading to 
improvement  in  neuronal  function  and  inhibition  of  cell 
death [38]. In a single-country multi-site randomised clinical 
trial, latrepirdine was shown to be significantly superior to 
placebo on measures of cognition (ADAS-cog and MMSE), 
global evaluation (CIBIC), function (ADCS-ADL) and be-
haviour (NPI) at 26 weeks. It was relatively well tolerated, 
the most common adverse events being dry mouth and de-
pressed  mood.  Several  large  scale  phase  III  randomised 
clinical  trials  with  latrepirdine  are  ongoing.  If  these  trials 
replicate the findings of the initial study,  latrepirdine  may 
very well be the next pharmacological agent to be commer-
cialized for symptomatic treatment of AD.  
Other Treatments 
  All  currently  available  treatment  options  for  AD  are 
symptomatic and do not modify natural progression of the 
disease. Disease-modifying approaches are constantly being 
explored.  Several  agents  under  study  target  the  amyloïd  
cascade. They can be divided into three general categories: 
agents aiming at decreasing the production of Aβ, at reduc-
ing its  aggregation, or at  increasing its clearance [57, 71]. 
Agents that can decrease production of Aβ include gamma-
secretase inhibitors [48, 116] or modulators [129] as well as 
alpha-secretase activators [76]. For Aβ to aggregate into in-
soluble toxic plaques, it needs to bind to metallic ions such 
as copper and zinc. Chelators inhibiting this binding such as 
clioquinol [101] have been proposed and studied in AD. Cy-
clohexanehexol  [88]  inhibits  aggregation  of  Aβ  into  high 
molecular  weight  toxic  oligomers  and  has  been  shown  to 
reverse pathological and clinical hallmark of AD in animal 
models. Recently completed, but yet unpublished, phase III 
clinical trials with the gamma-secretase modulator flurizan 
and  the  amyloid-binding  inhibitor  tramiprosate  showed 
largely negative results on primary end-points. Optimizing 
clearance of Aβ and its oligomers by immunization seemed 
very promising in animal models of AD [87]. A pilot study 
in patients with AD lead to an unexpected high rate of men-
ingoencephalitis leading to interruption of the trial [96]. Neu-
ropathologic findings in some patients enrolled in this study 
show  a  clear  association  between  high  pre-mortem  serum 
antibody response and clearance of amyloid deposits in the 
brain  cortex.  However,  there  was  no  association  between 
antibody response, amyloid deposition, and clinical findings 
[11,  65].  The  immunologic  approach  in  AD  is  still  being 
tested  in  trials  of  passive  immunization  with  intravenous 76    Current Neuropharmacology, 2010, Vol. 8, No. 1  Massoud and Gauthier 
immunoglobulins  and  monoclonal  antibodies  against  Aβ 
[132]. Several of the agents described are currently in phase 
II-III clinical trials. 
  Inhibition  of  protein  tau  phosphorylation  is  also  being 
explored in animal models and pilot human studies in AD. 
Agents in this category include glycogen synthase kinase 3-β 
(GSK3-β)  inhibitors  such  as  lithium  [94]  and  valproate 
[134], and microtubule stabilizing agents such as paclitaxel 
[133].  A  recently  completed  but  unpublished  phase  III  
clinical trial with valproate is negative.  
  Other agents being tested target oxidative stress in AD, 
neuroinflammation,  cholesterol  metabolism  and  the  neu-
roendocrine pathways [22, 71].  
  Development  of  disease-modifying  treatments  in  AD 
faces many challenges that will need to be considered in fu-
ture  research  and  clinical  trials.  Novel  pharmacological 
agents will need to cross the blood-brain barrier and be read-
ily bioavailable to the central nervous system. Several of the 
secretases being targeted have numerous substrates some of 
which are required for normal function. Hence, total inhibi-
tion  rather  than  modulation  may  lead  to  unacceptable  ad-
verse events. Transferring results of animal model research 
to humans has been fraught with obstacles as demonstrated 
by the immunization trials. Finally, methodology in clinical 
trials  will  need  to  be  adapted  to  detect  disease-modifying 
effect,  and  this  may  lead  to  longer  and  more  expensive  
studies.  
CONCLUSIONS 
  In  conclusion,  AD  is  a  common  and  costly  disease.  
Currently several symptomatic treatments are available that 
provide mild benefits that are nevertheless dose-dependent, 
clinically detectable, and reproducible across clinical trials. 
Sustained use of these medications needs to be improved for 
optimal benefit. This can be achieved by tailoring doses and 
titration to the individual patients to enhance tolerance, and 
mostly, setting realistic expectations  in face of  a neurode-
generative  disease  and  symptomatic  treatments.  Several 
agents  under  study  are  potentially  disease-modifying  and 
may significantly alter the otherwise inexorable deterioration 
in AD. It is such treatments that will significantly improve 
clinical symptoms of the disease and lead to robust pharma-
coeconomic  benefits  such  as  the  reduction  of  resource  
utilisation.  However,  when  expensive  disease-modifying 
agents will become available, they will present the clinician 
with  many  clinical  and  ethical  challenges  as  to  their  
indications, decisions to combine or discontinue treatments. 
These challenges will need to be considered in future clinical 
trials.  
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